Parnax Lab

Parnax Lab Financing Cash Flow

The Net Financing Cash Flow of Parnax Lab (506128.BO) as of Nov 2, 2026 is -158.15 M INR. In the previous year, Net Financing Cash Flow was 148.17 M INR — a change of -206.74% (lower).

Financing Cash Flow

-158.15 MINR

YoY

-206.74%

Last updated:

Net Financing Cash Flow of Parnax Lab is 2025 -158.15 M INR. Net Financing Cash Flow of Parnax Lab was 2024 148.17 M INR. It decreases by -206.74% lower compared to the previous year.

The Parnax Lab Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2018
-71.81 M INR
Jan 1, 2019
14.20 M INR
Jan 1, 2020
50.27 M INR
Jan 1, 2021
505,600.00 INR
Jan 1, 2022
121.34 M INR
Jan 1, 2023
-140.69 M INR
Jan 1, 2024
148.17 M INR
Jan 1, 2025
-158.15 M INR
The Parnax Lab Financing Cash Flow history
YEARFinancing Cash FlowYoY
-158.15 MINR-206.74%
148.17 MINR-205.32%
-140.69 MINR-215.95%
121.34 MINR+23,898.79%
505,600.00INR-98.99%
50.27 MINR+254.04%
14.20 MINR-119.77%
-71.81 MINR+1,010.46%
-6.47 MINR-189.84%
7.20 MINR-86.91%
54.97 MINR-11.98%
62.45 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Parnax Lab Stock analysis

What does Parnax Lab do? Parnax Lab Ltd. generates revenue through manufacturing and exporting pharmaceutical formulations, including cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, geriatric special formulations, highly viscous products, and suspensions. The company trades pharmaceuticals and medicinal products, focusing on high-volume oral formulations for diverse consumer segments. Naxpar Pharma Private Limited serves as its subsidiary in these operations. The firm's primary customers are likely healthcare providers, pharmacies, and distributors within the pharmaceutical industry, though specific buyer details are not disclosed. Parnax Lab Ltd. operates through the pharmaceutical formulations segment, emphasizing export-driven manufacturing and trading activities. Its product portfolio targets various health needs, from pediatric to geriatric care, with a strong focus on oral delivery systems. Parnax Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Parnax Lab stock

Net Financing Cash Flow of Parnax Lab is -158.15 M INR in 2025.

Net Financing Cash Flow of Parnax Lab changed from 148.17 M INR to -158.15 M INR, representing a -206.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Parnax Lab since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Parnax Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Parnax Lab

All Key Metrics — Parnax Lab